Skip to main content

Advertisement

Table 4 Overall survival in relation to standard clinicopathological prognostic factors and the studied markers

From: Clinical significance of altered nm23-H1, EGFR, RB and p53 expression in bilharzial bladder cancer

   Univariate analysis Multivariate analysis
Predictive variables CS HR CI p HR CI p
Age        
   <47 68% 1 0.99, 1.02 0.880    
   ≥ 47 * 66%       
Sex:        
Male (42) 59% 1.1 0.85, 1.04 0.652    
Female (17) 64%       
Tumor type        
SCC (27) 60% 1.212, 0.538, 2.734 0.643    
TCC (27) 65%       
Adenocarcinoma (5) 60%       
Tumor grade        
I (5) 66% 1.96 1.66, 21.331 <0.000 4.350 1.786, 10.591 0.001
II (39) 32%       
III (15) 11%       
Lymph Node Involvement:   1.099 0.423, 2.859 0.846    
Positive (10) 49%       
Negative (49) 55%       
Metastatic recurrence:        
No (33) 58% 14.149 5.117, 39.123 0.000 14.903 5.315, 41.785 0.000
Yes (21) 25%       
Pathological Stage:        
p2 & pp3a (27) 49% 1.341 0.575, 3.127 0.498    
p3b &p4 (32) 35%       
Nm23 (IHC )        
Positive (34) 66.5% 1.62 0.535, 2.244 0.345    
Negative (25) 59.6%       
nm23(RNA )        
   Positive (33) 64.8% 1.34 1.20, 1.50 0.021 0.695 0.586, 1.975 0.444
   Negative (19) 35.5%       
EGFR (IHC)        
   Positive (39) 41% 1.61 1.04, 2.29 0.034 3.576 1.206, 10.602 0.022
   Negative (20) 69%       
EGFR (RNA)        
   Positive (32) 39% 1.69 1.16, 2.74 0.031 3.911 1.148, 8.511 0.025
   Negative (20) 69%       
Rb        
   Positive (25) 54% 1.1 0.27, 1.76 0.287    
   Negative (34) 49%       
p53 (IHC)        
   Positive (21) 29% 3.9 2.281, 12.42 0.011 2.512 0.948, 6.662 0.64
   Negative (38) 60%       
P53 (mutations)        
   Positive (8)     0.539    
   Negative (51)        
Number of abnormal genes   1.70 1.20, 5.90 0.022 7.331 2.696, 12.940 0.001
   <2        
    2        
  1. * The median age for the studied patients
  2. ** Data regarding metastatic recurrence was available for 54 cases only